Areas of Interest to
Wyeth's Pharmaceutical Division
Our partnering interests are highly varied and cover the whole spectrum from platform technologies, targets, and collaborations in support of the drug discovery effort to products in all stages of development or already on the market.
Cardiovascular and Metabolic Diseases
- Atherothrombosis
- Heart failure
- Type 2 diabetes
- Obesity
- Metabolic syndrome
- Diabetic vascular disease (nephropathy)
Neuroscience
- Chronic pain
- Alzheimer’s disease
- Parkinson’s disease
- Stroke
- Schizophrenia and bipolar disorder
- Depression and anxiety
Inflammation
- Rheumatoid arthritis
- Lupus
- Asthma
- COPD
- Psoriasis
- Multiple sclerosis
Women’s Health and Musculoskeletal Biology
- Osteoporosis
- Osteoarthritis
- Urinary incontinence
- Dermal therapies
- Alopecia
- Skin fragility
- Menopause and female sexual dysfunction
- Reproductive disorders
Oncology
- Non-small-cell lung cancer
- Breast cancer
- Colorectal cancer
- Prostate cancer
- Renal cancer
- B-cell malignancies
- Melanoma
Biotherapeutics
- Therapeutic antibodies (naked antibodies and antibody-drug conjugates)
- Non-antibody targeting scaffolds
- Therapeutic enzymes (eg, proteases)
- Novel delivery vehicles (eg, for peptides and nanoparticles)
Vaccines
- Disease-specific antigens for infectious and non-infectious diseases
- Immunomodulators, adjuvants, and vector systems to modulate immune response to vaccines
- Technology platforms for antigen identification/design, manufacture, and delivery of vaccines
Infectious Disease
- New classes of antibiotics with improved resistance, tolerability, and efficacy profiles
- Technologies and compounds for overcoming resistance
- Devices and formulations for delivering antibiotics
- Antifungals exhibiting profiles that are differentiated from current classes
- Antivirals
- Novel combination therapies
Hematology
- Clotting factors
- Antithrombotic factors
- Anemia
- Bleeding disorders
Technologies
- Medicinal chemistry
- Analytical chemistry
- Natural products
- Structural biology
- Computational chemistry
- Protein technologies
- Genomics
- Bioinformatics
- Genetically modified animals
- Translational medicine/biomarkers
Special Opportunities
Opportunities in areas where we do not have an in-house discovery effort require clinical proof of concept to be of interest.
- Anti-infectives
- Gastrointestinal
- Ophthalmology
- Dermatology
Regional Business Development
Wyeth’s Regional Business Development Group is dedicated to regional licensing and business development. The Group focuses on late-stage opportunities (Phase III or beyond) across all therapeutic areas for all or any of the following regions:
- Asia-Pacific (ex-Japan)
- Japan
- Europe, Middle East, Africa (EMEA)
- Canada
- Latin America
Such opportunities can be exclusive licenses, co-promotion, or co-marketing.
235839-01